奈拉滨治疗T细胞急性淋巴细胞白血病:细胞内代谢与分子作用机制
本文对奈拉滨治疗T细胞急性淋巴细胞白血病(T-ALL)的临床前文献进行半系统综述,评估其分子药理学知识。早期研究确定ara-G三磷酸为主要活性代谢物、核DNA合成为关键靶点,但DNA损伤性质与修复、ara-G代谢物的其他细胞靶点及其在疗效与毒性中的作用等基本问题仍未解决,奈拉滨联合治疗是亟需研究的方向。
要点
- 奈拉滨是临床实践中唯一T-ALL特异性药物,为脱氧鸟苷类似物ara-G的前药,选择性作用于T细胞恶性肿瘤。
- 早期研究确定ara-G三磷酸为主要活性代谢物,核DNA合成为关键靶点。
- 奈拉滨诱导的DNA损伤性质与修复、ara-G代谢物的其他细胞靶点及其在疗效与毒性中的作用等基本问题仍未解决。
核心结论
- 早期研究确定ara-G三磷酸为主要活性代谢物、核DNA合成为关键靶点,但许多可指导未来治疗应用的基本问题仍未解决。
- 奈拉滨联合治疗(与现行T-ALL化疗方案及新兴抗白血病药物联合)是亟需研究的关键方向,本文指出了若干值得探索的领域。
研究设计与样本
- 本文为对文献的半系统综述,批判性评估奈拉滨分子药理学的临床前知识。
主要发现
- 早期研究确定ara-G三磷酸为主要活性代谢物,核DNA合成为关键靶点。
- 奈拉滨诱导的DNA损伤性质及其修复、ara-G代谢物的其他细胞靶点及其在疗效与毒性中的作用等基本问题仍未解决。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文指出,尽管奈拉滨的临床使用已有多篇综述,但详细阐述其抗白血病活性分子基础的临床前数据缺乏全面概述。
- 原文指出,许多可指导未来治疗应用的基本问题仍未解决,包括奈拉滨诱导的DNA损伤性质及其修复、ara-G代谢物的其他细胞靶点及其在疗效与毒性中的作用。
- 原文指出,奈拉滨联合治疗的研究亟需开展。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
T-cell acute lymphoblastic leukemia (T-ALL) patients often have a poor 5-year event-free survival. The only T-ALL specific drug in clinical practice is nelarabine. A prodrug of the deoxyguanosine analog ara-G, nelarabine is a rationally designed agent selective for the treatment of T-cell malignancies. Originally approved for relapsed/refractory T-ALL, it is increasingly used in T-ALL therapy and is currently being evaluated in upfront treatment. Whilst the clinical use of nelarabine has been the topic of multiple review articles, a thorough overview of the preclinical data detailing the molecular underpinnings of its anti-leukemic activity is lacking, which is critical to inform mechanism-based use. Thus, in the present article we conducted a semi-systematic review of the literature and critically evaluated the preclinical knowledge on the molecular pharmacology of nelarabine. Whilst early studies identified ara-G triphosphate to be the principal active metabolite and nuclear DNA synthesis to be a key target, many fundamental questions remain that could inform upon future use of this therapy. These include the nature of nelarabine-induced DNA lesions and their repair, together with additional cellular targets of ara-G metabolites and their role in efficacy and toxicity. A critical avenue of research in need of development is investigation of nelarabine combination therapies, both in the context of current T-ALL chemotherapy regimens and with emerging anti-leukemic agents, and we highlight some areas to pursue. Altogether, we discuss what we can learn from the preclinical literature as a whole and present our view for future research regarding nelarabine treatment in T-ALL.
引用
- Hormann FM, Rudd SG. Nelarabine in T-cell acute lymphoblastic leukemia: intracellular metabolism and molecular mode-of-action. Leukemia. 2025. PMID: 39962329. doi:10.1038/s41375-025-02529-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。